Berberine, a potential bitter agonist for TAS2R38 and TAS2R46 (86), exerts a protective effect in inhibiting inflammatory responses and has a long history in the treatment of inflammatory bowel diseases (87, 88). The gene discussed is TAS2R46; the disease is inflammatory bowel disease.